Ongoing Clinical Studies in Bladder Cancer

Cretostimogene grenadenorepvec (CG0070) is currently being evaluated in multiple studies including Phase 1b/2, Phase 2, and Phase 3 studies in the U.S. in BCG unresponsive NMIBC and MIBC. Two studies are actively recruiting. Studies are on-going in South Korea, Japan, China, Taiwan, Australia, and Canada.

TRIAL TITLE

TRIAL NUMBER
STAGE
STATUS
PUBLICATION

BOND-002

Safety and Efficacy

Phase 2, US only

Completed

BOND-003

Phase 3

Phase 3, Global (US, Japan, South Korea, Taiwan, Australia, Canada)

CORE-001

Phase 2, CG0070 Combined With Pembrolizumab

Phase 2, Global (US, South Korea)

Active, Not Recruiting

CORE-002

Phase 1 Study With Nivolumab Ineligible Cisplatin with MIBC

Phase 1b/2, US Only

Recruiting

Patients and Urologists interested in participating should contact:

JoAnn Horn
phone: 516-456-1415
joann.horn@CGOncology.com.

Partners

CG Oncology is eager to partner with companies who share our passion for improving patients and their loved one’s lives. Collaborations could be in R&D, business development or clinical trials. Our partners include:

  • Merck
  • Bristol Myers Squibb
  • Roche
  • Kissei Pharmaceutical Co.
  • LEPU Medical Holdings
  • FUJIFILM Diosynth Biotechnologies

If you are interested in becoming a partner with us, please contact us at bd@cgoncology.com